Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Combinatorial genetics uncovers novel targets for the treatment of Npm1/cohesin mutated AML
    Meeting Abstract

    Meyer, A. E.; Stelloh, C.; Fisher, J. B.; Pulakanti, K.; Vassiliou, G. S.; Viny, A. D.; Levine, R. L.; Rao, S.
    Blood (2019)

    Fulltext@MSK | Save
  • A phase Ib/II study of the histone methyltransferase inhibitor pinometostat in combination with azacitidine in patients with 11q23-rearranged acute myeloid leukemia
    Meeting Abstract

    Menghrajani, K.; Cai, S. F.; Devlin, S. M.; Armstrong, S. A.; Piekarz, R.; Rudek, M.; Tallman, M. S.; Stein, E. M.
    Blood (2019)

    Fulltext@MSK | Save
  • Overcoming adaptive therapy resistance in AML by targeting immune response pathways
    Meeting Abstract

    Melgar, K. M.; Jones, L. M.; Walker, M.; Bolanos, L. C.; Hueneman, K.; Wunderlich, M.; Jiang, J. K.; Wilson, K.; Zhang, X.; Sutter, P.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Significance of abnormalities of PPM1D in myeloproliferative neoplasms
    Meeting Abstract

    Marcellino, B.; Tripodi, J.; Bar-Natan, M.; Fruchtman, H.; Farnoud, N.; Lu, M.; Kosiorek, H. E.; Dueck, A. C.; Rampal, R. K.; Mascarenhas, J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Bone marrow morphologic findings in patients receiving IDH inhibitor therapy in combination with intensive induction chemotherapy: Challenges with interpretation of the day 14 bone marrow biopsy
    Meeting Abstract

    Mason, E. F.; Pozdnyakova, O.; Roshal, M.; Fathi, A. T.; Stein, E. M.; Shaver, A. C.; Frattini, M. G.; Wang, H.; Hua, L.; Mu, J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Treatment sequences and outcomes of patients with CLL treated with venetoclax and other novel agents post introduction of novel therapies
    Meeting Abstract

    Mato, A. R.; Sail, K.; Yazdy, M. S.; Hill, B. T.; Shadman, M.; Manzoor, B. S.; Tuncer, H. H.; Allan, J. N.; Ujjani, C. S.; Sharmokh, S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Phase II randomized trial of gilteritinib vs midostaurin in newly diagnosed FLT3 mutated acute myeloid leukemia (AML)
    Meeting Abstract

    Luger, S. M.; Sun, Z.; Loghavi, S.; Lazarus, H. M.; Rowe, J. M.; Tallman, M. S.; Pratz, K. W.; Litzow, M.
    Blood (2019)

    Fulltext@MSK | Save
  • Transcriptome profiling of pediatric myeloproliferative neoplasms demonstrates dysregulation of platelet-relevant genes and enrichment of inflammatory and JAK2 mediated complement pathways
    Meeting Abstract

    Kucine, N.; Leonti, A. R.; Krishnan, A.; Ries, R. E.; Levine, R. L.; Meshinchi, S.
    Blood (2019)

    Fulltext@MSK | Save
  • Evaluation of biomarkers as predictors of blinatumomab toxicity and real-world management of blinatumomab toxicity in B-acute lymphoblastic leukemia patients
    Meeting Abstract

    King, A. C.; Park, J. H.; Geyer, M. B.
    Blood (2019)

    Fulltext@MSK | Save
  • Real world chart review of blinatumomab to treat patients with high disease burden of relapsed or refractory B-cell precursor acute lymphoblastic leukemia
    Meeting Abstract

    King, A. C.; Bolanos, R.; Velasco, K.; Tu, H.; Zaman, F.; Geyer, M. B.; Park, J. H.
    Blood (2019)

    Fulltext@MSK | Save